Yanis Tolstov1, Boris Hadaschik2, Sascha Pahernik2, Markus Hohenfellner2, Stefan Duensing3. 1. Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany. 2. Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany. 3. Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany; Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany. Electronic address: stefan.duensing@med.uni-heidelberg.de.
Abstract
OBJECTIVES: Infection with human papillomaviruses (HPVs) is intimately associated with anogenital tract malignancies including cervical and vulvar cancer, a subset of oropharyngeal cancers and certain types of skin cancer. A number of urological tumors have likewise been suggested to be associated with high-risk HPV infection; however, many studies are hampered by a limited number of detection methods. The goal of this review article is to define a set of key criteria when implicating a virus in a human cancer and to apply these criteria to HPV infection in urological cancers. MATERIALS AND METHODS: We performed a survey of the literature to corroborate the evidence to support a causal relationship between HPV infection and major urological malignancies. RESULTS: A number of previous reports have implicated HPVs in urological malignancies including penile, prostate, and bladder cancer. Most reports, however, rely only on a limited number of detection methods and frequently use contamination-prone polymerase chain reaction based methods. To firmly establish a link between a viral infection and a human malignancy, it is paramount that an array of techniques is employed and that the virus is ultimately traced by either direct visualization or, in the case of viral genome that has integrated into the host genome, detection of viral genes and gene products as well as functional cellular perturbations. In any case, seroepidemiological studies are likewise crucial to support the evidence. Such evidence for a role of HPV in urological malignancies based on currently available techniques is only present for penile squamous cell carcinomas. CONCLUSIONS: An increasing number of immunocompromised patients as well as novel developments in patient care may change the spectrum of HPV-associated neoplasms. This is examplified by results demonstrating a role of HPVs in rare urothelial carcinomas with squamous differentiation in patients with neurogenic bladder. Hence, it is important to keep HPV infection in mind when confronted with unusual disease manifestations of the urogenital tract.
OBJECTIVES: Infection with human papillomaviruses (HPVs) is intimately associated with anogenital tract malignancies including cervical and vulvar cancer, a subset of oropharyngeal cancers and certain types of skin cancer. A number of urological tumors have likewise been suggested to be associated with high-risk HPV infection; however, many studies are hampered by a limited number of detection methods. The goal of this review article is to define a set of key criteria when implicating a virus in a humancancer and to apply these criteria to HPV infection in urological cancers. MATERIALS AND METHODS: We performed a survey of the literature to corroborate the evidence to support a causal relationship between HPV infection and major urological malignancies. RESULTS: A number of previous reports have implicated HPVs in urological malignancies including penile, prostate, and bladder cancer. Most reports, however, rely only on a limited number of detection methods and frequently use contamination-prone polymerase chain reaction based methods. To firmly establish a link between a viral infection and a humanmalignancy, it is paramount that an array of techniques is employed and that the virus is ultimately traced by either direct visualization or, in the case of viral genome that has integrated into the host genome, detection of viral genes and gene products as well as functional cellular perturbations. In any case, seroepidemiological studies are likewise crucial to support the evidence. Such evidence for a role of HPV in urological malignancies based on currently available techniques is only present for penile squamous cell carcinomas. CONCLUSIONS: An increasing number of immunocompromised patients as well as novel developments in patient care may change the spectrum of HPV-associated neoplasms. This is examplified by results demonstrating a role of HPVs in rare urothelial carcinomas with squamous differentiation in patients with neurogenic bladder. Hence, it is important to keep HPV infection in mind when confronted with unusual disease manifestations of the urogenital tract.
Authors: Renate Pichler; Wegene Borena; Georg Schäfer; Claudia Manzl; Zoran Culig; Sebastian List; Sabrina Neururer; Dorothee Von Laer; Isabel Heidegger; Helmut Klocker; Wolfgang Horninger; Hannes Steiner; Andrea Brunner Journal: World J Urol Date: 2015-03-19 Impact factor: 4.226
Authors: Mehmet Sarier; Ali Murat Ceyhan; Nevgun Sepin; Esin Ozel; Mehmet Murat Inal; Erdal Kukul; Ahmet Soylu Journal: Int Urol Nephrol Date: 2019-10-03 Impact factor: 2.370
Authors: Sebastian C Schmid; Leonore Thümer; Tibor Schuster; Thomas Horn; Florian Kurtz; Julia Slotta-Huspenina; Judith Seebach; Michael Straub; Tobias Maurer; Michael Autenrieth; Hubert Kübler; Margitta Retz; Ulrike Protzer; Jürgen E Gschwend; Dieter Hoffmann Journal: Infect Agent Cancer Date: 2015-09-21 Impact factor: 2.965